Immunovant, Inc.
IMVT
$15.80
-$0.06-0.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.21% | -1.84% | -25.21% | -15.71% | -46.48% |
| Total Depreciation and Amortization | 10.10% | 11.24% | 11.25% | 25.00% | 10.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.29% | -8.18% | -5.96% | 36.15% | -5.55% |
| Change in Net Operating Assets | -1,434.61% | -113.60% | 389.36% | -147.11% | 189.96% |
| Cash from Operations | -10.21% | -13.25% | -16.34% | -27.64% | -26.75% |
| Capital Expenditure | -11.67% | 8.16% | -7.69% | -21.33% | -14.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -11.67% | 8.16% | -7.69% | -21.33% | -14.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 18,200.77% | 237.53% | 6.41% | -55.60% | -99.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 18,187.82% | 237.53% | 6.41% | -55.60% | -99.67% |
| Foreign Exchange rate Adjustments | -227.52% | -114.20% | 213.13% | -87.74% | 270.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 445.31% | -12.85% | -15.53% | -35.61% | -113.20% |